SMR Stock Slides As Wall Street Resets Long-Shot Nuclear Bet

NuScale Power Corporation stocks have been trading down by -6.11 percent following bearish sentiment over small modular reactor commercialization.

Live Update At 16:47:06 EDT: On Thursday, September 10, 2026 NuScale Power Corporation stock [NYSE: SMR] is trending down by -6.11%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

SMR has been acting like a classic story stock on the chart. Over the last few weeks, NuScale Power has ground higher from the high-$8s to above $11, then pulled back to close near $10.21 on 2026/09/10. That’s still a solid bounce off August lows around $8.50–$9.00, but the recent fade shows traders taking profits and reassessing risk.

Intraday, SMR traded in a tight band between roughly $10.10 and $10.30 for most of the latest session, with early strength above $10.60 failing and rolling over. That intraday action tells traders the breakout buyers are getting tested and momentum is cooling.

Fundamentals paint the same picture. NuScale Power reported just $75,000 in Q2 revenue against operating expenses of about $63.9M and a net loss near $47.5M. Profitability ratios are deeply negative, and price-to-sales near 449x screams “speculative.” At the same time, SMR’s balance sheet is loaded: roughly $1.07B in cash and short-term investments and no meaningful debt, backing a current ratio near 38. For traders, that combination—big cash, big burn, and no profits—signals a long-duration commercialization story where headlines, not earnings, will drive the next big move.

Why Traders Are Locked In On SMR

SMR is one of those names where the story is huge and the numbers are harsh. NuScale Power is still the only small modular reactor developer with Nuclear Regulatory Commission design certification. That regulatory edge is real. It gives SMR a first-mover status in a field that could reshape baseload power for decades. On top of that, NuScale Power holds roughly $1.9B in cash and investments, which sharply reduces near-term bankruptcy risk and gives the company runway to keep developing its technology.

But here’s the friction point every SMR trader has to respect: there are still no binding module orders. Revenue is tiny, losses are big, and the gap between regulatory progress and commercial adoption remains wide. Until NuScale Power converts that pipeline into signed, enforceable contracts, the stock trades on hope and timelines.

Wall Street is recalibrating around that reality. RBC Capital cut its SMR price target from $14 to $10 after Q2 revenue missed expectations and questions around project timing lingered. The bank still calls NuScale Power “Sector Perform,” not a disaster, but expectations are coming down. Other analysts sit in the same camp, with SMR carrying an average Hold rating and a mean target near $12.63—basically a “prove it” stance.

Add in a Form 144 from an insider or major holder planning to sell shares, and traders get one more caution flag. Insider selling does not always mean trouble, but extra supply can cap rallies. For active SMR traders, the message is clear: treat this as a volatile, catalyst-driven nuclear-tech trade, not a steady compounder.

Conclusion

NuScale Power is a pure execution story right now. SMR’s NRC-certified design and roughly $1.9B war chest give the company a serious shot at shaping the future of nuclear power. The balance sheet is strong, the tech lead is real, and that’s why traders keep coming back to SMR whenever nuclear headlines heat up.

But the current financials tell a different tale. Q2 revenue was almost a rounding error next to more than $63M in operating expenses, and the key profitability metrics are deeply in the red. With RBC cutting its price target to $10 and labeling SMR as speculative, the Street is demanding hard proof: binding module orders, clearer project timing, and a path toward meaningful revenue. The Form 144 selling intent only adds another layer of near-term supply risk for NuScale Power traders trying to ride the trend.

For active traders who study charts and catalysts, SMR sits in that classic high-potential, high-uncertainty pocket. It can run hard on good news and unwind just as fast when timelines slip. As Tim Sykes likes to say, “The market doesn’t care about your dreams; it cares about catalysts and risk.” That’s why discipline matters for anyone trading names like SMR; as millionaire penny stock trader and teacher Tim Sykes, says, “There is always another play around the corner; don’t chase just because you feel FOMO.”. With NuScale Power, the next real catalyst is simple to define and tough to predict—the first big, binding order that proves this nuclear story is finally turning into a business.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

• Penny Stocks Trading Guide
• Best Penny Stocks Under $1 to Buy Today
• Top 8 Penny Stocks to Watch on Robinhood

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

• AI Penny Stocks
• Robinhood Penny Stocks
• Top Biotech Stocks